Skip to content

Study of AYUSH KWATH in quarantine persons

Evaluation of the efficacy of AYUSH KWATH in the prevention of COVID-19 pandemic among quarantine persons â?? an open label single arm prospective study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/06/025779
Enrollment
50
Registered
2020-06-10
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Drug Interventions (Ayush Kwath): 1. Tulasi (Ocimum sanctum) Leaves 4 parts 2. Dalchini (Cinnamomum zeylanicum ) Stem bark 2 parts 3. Shunthi (Zingiber officinalis) Rhizome 2 parts 4. K

Sponsors

Dr SR Rajasthan Ayurveda UniversityJodhpurRaj
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. All persons who got admitted in Quarantine center of 20 to 60 years willing to participate, with or without co-morbid condition with exposure/chance of exposure to COVID 19 positive cases. 2. Who are willing to provide signed informed consent

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating females. 2. Known case of Carcinoma lungs, CRF and CHF. 3. Participants with any immunosuppressive medication or in an immune compromised state or hematological disease. 4. Laboratory confirmed COVID-19 with or without symptoms. 5. DM uncontrolled with medications. 6. Any other criteria, as per the investigator would jeopardize the study.

Design outcomes

Primary

MeasureTime frame
Percentage of participants with SARS- Cov-2 positivity and Number/ percentage of participants not developing any Covid-19 like sign & symptoms (Time line 30 days)Timepoint: Percentage of participants with SARS- Cov-2 positivity and Number/ percentage of participants not developing any Covid-19 like sign & symptoms (Time line 30 days)

Secondary

MeasureTime frame
Safety profile of the intervention as estimated by LFT, KFT and other hematological & biochemical investigations. (Time frame: 30 days) 1. Presence or absence of AE/ADR and their level of tolerability 2. Number of participants who developed any infective diseases during the trial period (bacterial /viral/ fungal / etc.) and percentage of participants with Upper respiratory tract illness during the period.Timepoint: 30 days

Countries

India

Contacts

Public ContactProf Dr Abhimanyu Kumar

Dr SR Rajasthan Ayurveda University,Jodhpur(Raj.)

vc.dsrrau@gmail.com8800543828

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026